Detalhe da pesquisa
1.
A novel mechanism-based pharmacokinetic-pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against ß-lactamase-producing Gram-negative bacteria.
J Antimicrob Chemother
; 75(2): 400-408, 2020 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31670804
2.
Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen.
J Antimicrob Chemother
; 74(10): 2984-2993, 2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31273375
3.
Population Pharmacokinetics of Piperacillin in Sepsis Patients: Should Alternative Dosing Strategies Be Considered?
Antimicrob Agents Chemother
; 62(5)2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29507062
4.
Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model.
J Antimicrob Chemother
; 71(5): 1279-90, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26850719
5.
Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs.
Pharm Res
; 33(5): 1115-25, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26786016
6.
Erratum to: Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen.
J Antimicrob Chemother
; 75(1): 254-255, 2020 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31650174
7.
Inter occasion variability in individual optimal design.
J Pharmacokinet Pharmacodyn
; 42(6): 735-50, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26452548
8.
Quantifying combined effects of colistin and ciprofloxacin against Escherichia coli in an in silico pharmacokinetic-pharmacodynamic model.
Sci Rep
; 14(1): 11706, 2024 05 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38778123
9.
Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli.
Int J Antimicrob Agents
; 51(3): 399-406, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29127049
10.
Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.
BMJ Open
; 6(4): e009956, 2016 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27098822